Cure My Disease

Don't miss your cure!

 Log in / Sign up

A pharmacist in the dentist's chair: could a new team approach tame stubborn mouth conditions?

NCT ID NCT07721090

Disease control Sponsor: University of Fujairah Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This trial tests whether adding a clinical pharmacist to dental care can improve how oral mucosal disorders — such as oral lichen planus, recurrent canker sores, burning mouth syndrome, oral thrush, and herpes infections — are managed. Dentists in some clinics will get pharmacist support to review prescriptions, counsel patients, and monitor for side effects. The study will compare prescribing quality, medication adherence, and symptom control between clinics using this model and those providing usual care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a pharmacist-led prescribing optimization and patient counselling program
What this could lead to
If effective, this model could become a standard way to improve medication safety and symptom control for common oral conditions in dental clinics.
What could go wrong
This is a relatively small, early-stage implementation trial. The benefit may depend on clinic resources and may not generalize to all settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 336 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years and above * Diagnosed with an oral mucosal disorder (oral lichen planus, recurrent aphthous stomatitis, burning mouth syndrome, Herpes viral infection or oral candidiasis) * Attending participating dental clinic sessions during the study period * Prescribed pharmacological treatment for the oral mucosal condition * Able and willing to provide written informed consent Exclusion Criteria: * Patients without a confirmed diagnosis of an oral mucosal disorder * Patients requiring immediate emergency care or hospitalization * Patients currently enrolled in another interventional clinical trial * Known hypersensitivity to commonly prescribed medications used in the study * Patients unable to comply with follow-up or study procedures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Burning mouth syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aphthous stomatitis burning mouth syndrome canker sore Herpesviridae infectious disease lichen planus, oral oral candidiasis Patient Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Burning mouth syndrome Herpes virus infection Oral candidiasis Oral lichen planus Recurrent aphthous stomatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.